Verofylline

Verofylline

SCHEMBL636856

CCC(C)Cn1c(=O)n(C)c(=O)c2[nH]c(C)nc21

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 4/20 0.78
PDE1B Q01064 4/20 0.78
PDE1C Q14123 4/20 0.78
PDE2A O00408 3/20 0.78
PDE5A O76074 9/20 0.54
CYP1A2 P05177 3/20 0.52
CYP3A4 P08684 3/20 0.52
MEN1 O00255 2/20 0.52
CYP2C19 P33261 2/20 0.52
BLM P54132 2/20 0.52
KMT2A Q03164 2/20 0.52
TSHR P16473 2/20 0.52
MAPK1 P28482 2/20 0.52
LMNA P02545 1/20 0.52
CYP1A1 P04798 1/20 0.52
NFKB1 P19838 1/20 0.52
PMP22 Q01453 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HIF1A Q16665 1/20 0.52
PDE3B Q13370 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11607287 0.90 PDE1A (0.74) PDE1APDE1BPDE1CPDE2APDE5A
SCHEMBL897036 0.87 PDE1A (1.00) PDE1APDE1BPDE1CPDE2APDE5A
SCHEMBL7475458 0.87 PDE1A (0.59) PDE1APDE1BPDE1CPDE2APDE5A
SCHEMBL10963761 0.85 PDE5A (0.60) PDE1APDE1BPDE1CPDE2APDE5A
SCHEMBL25249437 0.79 PDE1A (0.69) PDE1APDE1BPDE1CPDE2APDE5A
SCHEMBL13368836 0.78 PDE2A (0.47) PDE1APDE1BPDE1CPDE2APDE5A
SCHEMBL10855561 0.76 PDE2A (0.73) PDE1APDE1BPDE1CPDE2AADORA1
SCHEMBL2917587 0.76 PDE1A (0.78) PDE1APDE1BPDE1CPDE2APDE5A
SCHEMBL6869474 0.75 PDE1A (0.72) PDE1APDE1BPDE1CPDE2APDE5A
SCHEMBL461786 0.74 PDE2A (0.62) PDE1APDE1BPDE1CPDE2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931320-B1 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME FLAMEL IRELAND LTD (IE) 2022-06-15 EP claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
US-20090220611-A1 Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same FLAMEL TECHNOLOGIES, S.A. (FR) 2009-09-03 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
CN-101277684-A Microparticles for the modified release of at least one active principle and oral pharmaceutical forms containing them FLAMEL TECH SA (FR) 2008-10-01 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
EP-1931320-A2 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME Flamel Technologies (FR) 2008-06-18 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
WO-2007036671-A2 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME FLAMEL TECHNOLOGIES (FR) 2007-04-05 WO claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
US-4089959-A Long-acting xanthine bronchodilators and antiallergy agents COOPER LABORATORIES, INC. (US) 1978-05-16 US claimed
EP-4706683-A2 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2026-03-11 EP disclosed
US-4089959-A Long-acting xanthine bronchodilators and antiallergy agents COOPER LABORATORIES, INC. (US) 1978-05-16 US disclosed